INN monograph
Aminacrine/Lignocaine oral gel
Therapeutic agent (verify pharmacological class) · POM
Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; PubChem; Component monographs (multi-source pipeline); Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Kenya market
Wholesale / list prices where loaded
Risk first
Contraindications
- [From component Lignocaine + Adrenaline injection] Children below 12yrs.
- Allergy to any component of the formulation.
- Use on fingers, toes, the tip of nose, ears, and penis since the product contains adrenaline.
Precautions
- Obtain allergy and medication history.
- Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
- Use the lowest effective dose for the shortest appropriate duration.
- Monitor for expected class adverse effects.
Point of care
Dosing
Adult
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Renal
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Safety
Drug interactions
- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Lignocaine + Adrenaline injection.
- Confirm combination SmPC for exact dosing.
Safety
Adverse effects
- [From component Lignocaine + Adrenaline injection] Acute toxic reactions in case of accidental intravascular injection.
- Drowsiness
- dizziness
- disorientation
- confusion
- lightheadedness
- psychosis
- apprehension
- tinnitus
- visual disturbances including amblyopia or diplopia
- vomiting
- paraesthesia
- sensations of heat, cold, or numbness
- difficulty swallowing
Use
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Painful mouth and throat infection
Pharmacology
Mode of action
Combination product.
Full mechanism text
Combination product. Component mechanism (Lignocaine + Adrenaline injection): Lignocaine acts by stabilizing the membranes of the nerve cells by decreasing their permeability to sodium ions. Adrenaline, a vasoconstrictor, prevents the extensive spread of lignocaine.
ADME
Pharmacokinetics & PD
| Onset | Product-specific |
|---|---|
| Duration | Product-specific |
| Route | See product SmPC |
| Elimination | are product-specific. Consider food effects, protein binding, hepatic CYP/UGT |
| Half-life | when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC. |
Full PK/PD text
Absorption, distribution, metabolism and excretion are product-specific. Consider food effects, protein binding, hepatic CYP/UGT metabolism, renal clearance and half-life when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Kenya
Brands & prices
| Brand | Company | Pack | KES |
|---|---|---|---|
| No brands linked yet. | |||
Special populations
Pregnancy & lactation
Pregnancy
[Aminacrine] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Lignocaine oral] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Lactation
[Aminacrine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Lignocaine oral] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Diet
Food & alcohol
- Food
- Food
Trust
Sources & disclaimer
Source: Local active-ingredient clinical extract; PubChem; Component monographs (multi-source pipeline); Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewed: 01 Aug 2026
Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.